PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients | Zendy

Hiroji Iwata | Zendy; SeockAh Im | Zendy; Norikazu Masuda | Zendy; YoungHyuck Im | Zendy; Kenichi Inoue | Zendy; Yoshiaki Rai | Zendy; Rikiya Nakamura | Zendy; Jee Hyun Kim | Zendy; Justin T. Hoffman | Zendy; Ke Zhang | Zendy; C. Giorgetti | Zendy; Shrividya Iyer | Zendy; Patrick T. Schnell | Zendy; Cynthia Huang Bartlett | Zendy; Jungsil Ro | Zendy

Open Access

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients

Author(s) -

Hiroji Iwata,

SeockAh Im,

Norikazu Masuda,

YoungHyuck Im,

Kenichi Inoue,

Yoshiaki Rai,

Rikiya Nakamura,

Jee Hyun Kim,

Justin T. Hoffman,

Ke Zhang,

C. Giorgetti,

Shrividya Iyer,

Patrick T. Schnell,

Cynthia Huang Bartlett,

Jungsil Ro

Publication year - 2017

Publication title -

journal of global oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.002

H-Index - 17

ISSN - 2378-9506

DOI - 10.1200/jgo.2016.008318

Subject(s) - fulvestrant , palbociclib , medicine , metastatic breast cancer , oncology , breast cancer , neutropenia , placebo , anastrozole , cancer , febrile neutropenia , gynecology , estrogen receptor , chemotherapy , tamoxifen , pathology , alternative medicine

To assess efficacy and safety of palbociclib plus fulvestrant in Asians with endocrine therapy-resistant metastatic breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research